Laurion Capital Management LP Biomarin Pharmaceutical Inc Transaction History

Laurion Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $822,305 - $999,122	-11,504 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $854,517 - $1.07 Million	11,504 New	11,504 $887,000
Q3 2021 Nov 15, 2021	SELL	$74.77 - $85.47 $28.4 Million - $32.4 Million	-379,356 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$75.51 - $84.79 $263,076 - $295,408	3,484 Added 0.93%	379,356 $31.7 Million
Q1 2021 May 14, 2021	BUY	$74.73 - $90.69 $27.2 Million - $33 Million	363,899 Added 3039.33%	375,872 $28.4 Million
Q4 2020 Feb 12, 2021	BUY	$72.61 - $90.2 $869,359 - $1.08 Million	11,973 New	11,973 $1.05 Million
Q4 2019 Feb 13, 2020	SELL	$64.27 - $86.37 $2.58 Million - $3.46 Million	-40,066 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$67.4 - $85.11 $2.7 Million - $3.41 Million	40,066 New	40,066 $2.7 Million
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $21,317 - $28,214	-266 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$93.92 - $105.72 $24,982 - $28,121	266 New	266 $26,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.